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Previous investigations have estimated the human immunodeficiency virus type 1 (HIV) base pair substitution rate to be approximately 10−4 to
10−5 per round of viral replication, and HIV has been hypothesized to be more error-prone than other retroviruses. Using a single cycle reversion
assay, we unexpectedly found that the reversion rates of HIV, avian leukosis virus and Moloney murine leukemia virus were the same, within
statistical error. Because both the viral enzyme reverse transcriptase (RT) and cellular RNA polymerase II (RNAP) are required for viral
replication, we hypothesized that the similar reversion rates actually reflect the intrinsic error rate of RNAP, which is the enzyme common to all
three retroviruses in the reversion assay. To address this possibility, HIV vectors with the U3 region replaced by a reporter reversion cassette were
constructed and vector supernatant produced by transient transfection. All single integrant revertant cell lines showed the identical mutations at
both long terminal repeats. This indicates that either RNAP or another cellular enzyme is responsible for these reversions, or that HIV RT only
makes errors during first strand synthesis. Additionally, when HIV particles were rescued from an integrated vector as opposed to being produced
by transient transfection, the reversion rate was significantly lower, suggesting that one or more factors in the virus-producing cells plays a role in
the fidelity of retroviral replication. These results have implications regarding the fidelity of the transgene after transient transfection production of
lentiviral vector supernatants.
© 2006 Elsevier Inc. All rights reserved.Keywords: Lentiviral vector; Fidelity; Transient transfection; RNA polymerase IIIntroduction
Human immunodeficiency virus type 1 (HIV) is the
causative agent of AIDS, the acquired immunodeficiency
syndrome. Because it is able to infect non-dividing or
mitotically quiescent cells, HIV has enormous potential as a
gene transfer agent for a variety of primary or terminally
differentiated cell types. For more than a decade, the HIV
genome has been manipulated as a vector with increasing
sophistication. Additionally, many ex vivo and in vivo animal
studies have demonstrated successful lentivirus-mediated gene
transfer of a variety of primary cell types and tissues, suggesting
imminent widespread use in man for treatment of both inherited
and acquired disorders (Dupre et al., 2004; Nash et al., 2004;⁎ Corresponding author. Department of Medicine, Division of Infectious
Diseases and the Center for Cell and Gene Therapy, Baylor College of Medicine,
Houston, TX 77030, USA. Fax: +1 713 798 3586.
E-mail address: rsutton@bcm.tmc.edu (R.E. Sutton).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.12.037Sumimoto et al., 2004). The first HIV-based vector gene transfer
approach was recently initiated for ex vivo transduction of
peripheral blood T cells from advanced patients who are
seropositive for HIV (MacGregor, 2001).
Despite advances in vector design, for the most part,
lentiviral vector supernatants are produced by transient
transfection of 293T cells, using purified plasmid DNA
templates. The FDA-approved Phase I clinical trial involving
HIV + patients utilized concentrated vector that was produced
after transient transfection of 293 cells (MacGregor, 2001).
Although several HIV packaging cell lines have been
developed, compared to transient transfection, these typically
yield lower vector titers, and particle production may be
transient (lasting only 5–10 days) after induction of vesicular
stomatitis virus (VSV) G protein expression (Kafri et al., 1999;
Strang et al., 2005; Yoshida et al., 1997). There are two reports,
however, of HIV packaging cell lines with titers that approach
those of transient transfection and more prolonged vector
production (Ikeda et al., 2003; Ni et al., 2005). While transient
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laboratory-based experimental applications, it may not be very
amenable to clinical studies that may require hundreds of liters
of vector supernatant.
It is well-established that HIV mutates or evolves during
replication, which allows the virus to escape from both the
cellular and humoral immune response and to develop drug
resistance against all licensed anti-retroviral medications
(Barre-Sinoussi, 1996; Domingo et al., 1997; Johnson et al.,
2005). The rate at which HIV mutates, or the viral error rate, has
implications for gene transfer, as well as for anti-HIV drug and
vaccine development. Under immune or drug-selective pres-
sure, a virus that has rare sequence changes may pass through a
genetic bottleneck and become the dominant circulating
species.
This critical lack of fidelity of HIV has long been attributed
to reverse transcriptase (RT) (Goff, 1990). All tested RTs
demonstrate poor fidelity in vitro, especially when compared
against cellular DNA polymerases, partly due to an absence of
proof-reading function (O'Neil et al., 2002; Roberts et al.,
1988). The mutation rate can be influenced by multiple
variables including the exact assay conditions (e.g., dNTP and
salt concentrations), the mutation being introduced, the RT
being studied, and the sequence context (Golinelli and Hughes,
2002; Mansky et al., 2003). This makes it virtually impossible
to assign a single numerical value to the error rate, but in most
cases, it is on the order of 10−4 to 10−5 per nucleotide or base
pair per round of replication (Huang and Wooley, 2005;
Mansky, 1996a).
Cell-based assays have been established to measure the
fidelity of retroviruses, typically involving a single cycle of
replication using a cell line with an integrated vector encoding
the reporter gene and a defective provirus to provide missing
trans functions. Either forward or reverse genetic screens are
used to identify mutations in the reporter and also calculate the
fidelity. For HIV, forward genetic screens using LacZα peptide
or thymidine kinase resulted in error rates of 3.4 × 10−5 and
2.2 × 10−5 mutations/base pair/cycle, respectively (Huang and
Wooley, 2005; Mansky and Temin, 1995). Reversion assays
have also been used to estimate fidelity. For example, for
reversion of an amber codon, the mutation rate of spleen
necrosis virus (SNV) was 2 × 10−5 (Dougherty and Temin,
1988), whereas use of the forward LacZα peptide screen
showed that for the same virus the error rate per target bp was
1 × 10−5 (Mansky and Temin, 1994). Similarly the error rate for
bovine leukosis virus (BLV) was determined to be 5 × 10−6 per
bp, just two-fold lower than that of SNV (Mansky and Temin,
1994). Interestingly, there was a similar spectrum of bp
substitutions, frameshifts, deletions, and additions for SNV,
BLV, and HIV, suggesting that a common property of retroviral
replication was responsible for the observed mutations.
An RNA fingerprinting assay for murine leukemia virus
(MLV) AKV strain demonstrated a similar base substitution rate
of 2 × 10−5 (Monk et al., 1992). This was similar to the mutation
rate of 1.4 × 10−5 for the eukaryotic gene hG6PD, determined
by direct sequencing of integrated MLV vectors (De Angioletti
et al., 2002). Using an amber reversion assay, Varela-Echavarríaet al. determined the MLVerror rate to be 4.0 × 10−6, which was
three- to five-fold lower than other estimates of MLV fidelity
(Varela-Echavarria et al., 1992).
In all of the above studies, the reversion or forward mutation
rate was measured using virus produced from an integrated
provirus in a stable cell line. Although superficially similar in
most cases, the results may not be directly comparable since
variables such as exact method of vector production, producer
and target cell lines utilized, and reporter construct were often
not identical. An additional confounding factor was low viral
titer in many cases, which resulted in relatively few mutational
events that could be scored.
Multiple factors may influence HIV fidelity, including
cellular DNA deaminases (notably APOBEC3G (Lecossier et
al., 2003; Zhang et al., 2003)) and viral proteins such as Vpr
(Chen et al., 2004; Mansky, 1996b; Mansky et al., 2000).
Although the error rate of RT has been the subject of much
investigation, the contribution of cellular RNA polymerase II
(RNAP), which transcribes the full-length viral RNA prior to
packaging, to replicative fidelity has not been as well
studied. One report suggested that RNAP plays little role in
HIV error rate (O'Neil et al., 2002), and at present, there are
no reliable methods to measure RNAP fidelity in a cell-based
system.
Here, we establish a two-marker genetic reversion assay to
examine the fidelity of HIV and two other retroviruses. At least
under transient transfection conditions, the fidelity of all three
was the same, within statistical error. However, the fidelity of
HIV was significantly lower when vector was produced by
transient transfection compared to stable producer cell lines. In
addition, double copy, self-inactivating vectors showed
identical sequence changes in both long terminal repeats
(LTRs). The data are consistent with RNAP or another cellular
enzyme being responsible for most of the reversions made
when vector was produced by transient transfection. These
results suggest that precisely how vector supernatant is made
can influence the frequency of mutations in a transgene, and
this may have implications for lentiviral gene transfer and
transgene fidelity.
Results
HIV, MLV, and ALV have similar reversion rates
It has been suggested that HIV is much more error-prone
than other retroviruses (Achaz et al., 2004; Bakhanashvili et
al., 2004; Berkhout et al., 2001). We decided to test this
hypothesis by incorporating precisely the same bicistronic
reporter cassette encoding a mutant blasticidin resistance gene
(bsd), coupled by an internal ribosome entry sequence (IRES)
to enhanced yellow fluorescent protein (eYFP) into an HIV,
an ALV, and a MLV vector (Fig. 1A). In all three vectors, the
reporter cassette was driven off the viral LTR. A genetic
reversion assay was used to measure the frequency at which
single nucleotide or frameshift mutations were corrected. The
bsd gene, which contained either a single nucleotide mutation
that created an early stop codon or a frameshift mutation, was
Fig. 1. Two marker genetic reversion assay. (A) Schematic of HIV, ALV, and MLV vectors, each with the identical bicistronic reporter cassette. HIV vector had
deletions in vif, vpr, vpu, nef, and most of env. Left intact were gag, pol, tat, and rev. MLV vector encoded only the cassette, whereas ALV vector was replication
competent in avian cells. Splicing patterns for the reporter cassette are shown beneath the vectors. Gene products are not precisely to scale. (B) Sequence of frameshift
(FS) and single nucleotide (SN) null mutants of bsd, each of which resulted in complete loss of blasticidin deaminase function. Numbers are relative to the ATG start
codon; underlined nucleotides were those added such that the downstream sequence was out of frame. (C) Calculation of reversion rate. Note reversion rate was
normalized to WT bsd titers.
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was used to calculate reversion rate, as shown in Fig. 1C.
Note that both the eYFP and wt bsd titers were used for
normalization purposes. The reversion assay measures a
subset of all possible sequence changes in the target gene.
Some changes are silent and therefore not scored in the assay,
which is based on phenotypic selection. The reversion assay
is a means of comparison among viruses and methods of
vector production; it is not necessarily an accurate measure of
the mutation or error rate since it does not score all possible
sequence changes. It has been estimated that assays based on
phenotype score 40% of all sequence changes in the target
gene (O'Neil et al., 2002). Frameshift corrections may behave
somewhat similarly to a forward mutation since the correction
requires an insertion or deletion.
bsd was chosen because it is relatively short (∼400 bp),
selection in the presence of antibiotic is quite rapid (complete
within 5–7 days), and it is facile to sequence in its entirety. Inaddition, the single nucleotide or frameshift mutations chosen
were null over greater than seven orders-of-magnitude so that
any blasticidin-resistant cell colonies would be due to a
reversion within bsd, as demonstrated by PCR followed by
DNA sequencing. In the case of the HIV vector, because the
bicistronic expression cassette lies within nef, both bsd and
eYFP are translated from the last exon of a multiply-spliced
mRNA so that nonsense-mediated decay is non-operational. To
compare the reversion rates of the three retroviruses, pseudo-
typed vector particles were produced by transient transfection of
293T cells with vector and VSV G envelope expression
plasmids, and titered on 293T cells. All reversion rate
experiments were performed a minimum of two times, with
three measurements per virus per target cell line for each
experiment. Thus, the reversion rate measurement for each virus
is based on at least 2 × 107 target cells.
The resultant reversion rates were not significantly different
from each other (Fig. 2A), suggesting that either the fidelity of
Fig. 2. Measurement of retroviral reversion rates. (A) Reversion rate of VSV G-
pseudotyped HIV, ALV, and MLV vectors, as measured on 293T cells; P N 0.05
for all intervector comparisons. (B) Comparison of HIV reversion rates using
VSV G- or ADA-pseudotyped vector on HOS.CD4.CCR5 targets; P N 0.05. (C)
HIV reversion rate determined on 293T (closed diamond) and HeLa (closed
square) target cells; P N 0.05 for all intravector comparisons.
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that a shared replication factor is responsible for the errors
generated. For the SN1 mutation in HIV, ALV, and MLV
vectors, the reversion rates were 1.8 × 10−5, 1.8 × 10−5, and
1.9 × 10−5, respectively. For the SN2 mutation, the reversion
rates were 1.5 × 10−5, 1.7 × 10−5, and 1.2 × 10−5, respectively.
There were no significant differences when intervector
reversion rates for each mutant bsd gene were analyzed by
Student's t test. This was repeated several times with similar
results. It should be noted that the HIV vector utilized does not
encode vif, but the 293T cells do not express CEM15
(APOBEC3G) or APOBEC3F so that particular hypermutation
system is non-functional. In particular, the stop mutation
reversions could not be G to A changes, which are the vast
majority of mutations observed in the absence of Vif and the
presence of APOBEC3G (Goff, 2003; Lecossier et al., 2003).Additionally, the deaminases are not known to correct
frameshift mutations.
Reversion rate is independent of viral envelope and
transduction temperature
Because we were using VSV G-pseudotyped particles
which enter the cell through an endocytic pathway that is pH-
dependent, it is possible that the reversion rate is altered
compared to when an HIV envelope is used, especially since
HIV typically fuses directly with target cell plasma
membrane and the precise cellular machinery involved is
different. In order to address this, we prepared HIV vector
supernatants that had been pseudotyped with ADA, a
macrophage-tropic HIV envelope. Both VSV G- and ADA-
pseudotyped vector supernatants were tested on GHOST HI 5
cell targets that express both human CD4 and CCR5, and the
resulting reversion rates were not significantly different (Fig.
2B). For VSV G- and ADA- pseudotyped vectors, reversion
rates for the SN1 mutation were 1.5 × 10−5 and 9.5 × 10−6,
respectively. For the SN2 mutation, reversion rates for VSV
G- and ADA-pseudotypes were 8.1 × 10−6 and 8.7 × 10−6,
respectively. This suggests that despite the differences in the
way the two pseudotyped particles enter the cell, replicative
fidelity is the same and thus independent of immediate post-
entry events.
We also wished to determine whether the observed reversion
rate was dependent on the target cell type. VSV G-pseudotyped
HIV was used to transduce two human cell lines, 293T and
HeLa, and the resultant reversion rates determined. The
differences in the HIV reversion rate for the single nucleotide
and frameshift mutations on these target cell lines were not
statistically significant (Fig. 2C). This is consistent with the fact
that there are no host proteins in the target cells known to
participate in viral cDNA synthesis.
Although like most other laboratories, we grow all
mammalian cells at 37 °C, this is not the core temperature of
the typical hosts for ALV. Both chickens and quail have a core
body temperature of about 41.5 °C, and for mice, it ranges from
36 to 38 °C. We questioned if the reversion rate observed could
be temperature-dependent. HIV vector supernatant was pro-
duced transiently using 293T producers at 37 °C but tested on
target cells at both 37 °C and 41 °C. Reversion rates for HIV-
SN1-IY were 1.0 × 10−5 at 37 °C and 1.1 × 10−5 at 41 °C,
which were not significantly different (P N 0.05, data not
shown).
Reversions due to plasmid amplification in E. coli or transient
transfection do not contribute substantially to HIV reversion
rate
It is conceivable that the reversions observed were due to
mutations in the plasmid template that arose during
amplification in E. coli. Purified plasmid HIV vector DNA
(encoding both mutant and wild-type bsd) was used to stably
transfect 293T cells using the cationic lipid DOTAP, and
blasticidin-resistant colonies were selected. Although the
Table 1
Reversion rate after stable transfection
Plasmid a Stable transfection rate b Reversion rate c
pHIV-WT-IY 9.6 × 10−2 –
pHIV-FS1-IY 1.4 ± 1.1 × 10−8 1.5 ± 1.1 × 10−7
pHIV-SN1-IY 5.4 ± 3.5 × 10−8 5.6 ± 3.6 × 10−7
a Cells were transfected with 80 μg of plasmid using DOTAP, then selected in
blasticidin.
b Number of blasticidin-resistant colonies divided by number of input cells.
c Calculated as mutant transfection rate divided by WT transfection rate.
Table 2
Reversion rate after transient transfection
Source of DNAa Reversion rate b
Purified, untransfected plasmid 3.5 ± 1.0 × 10−7
Hirt lysate (7.5 μg plasmid transfected) 2.6 ± 1.4 × 10−7
Hirt lysate (75 μg plasmid transfected) 3.5 ± 3.0 × 10−7
P N 0.05 for all comparisons.
a Original plasmid was pTP123-TEM-E166Q.
b Determined by transforming electrocompetent E. coli with 10 ng plasmid
and plating on chloramphenicol or ampicillin + chloramphenicol plates.
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corrected, it was approximately 10−7, 1–2 orders of
magnitude lower than that measured after transient production
of vector supernatant (Table 1). Thus, it is unlikely that the
observed reversion rate was simply due to mutation of DNA
sequences during plasmid propagation in the bacterial host E.
coli.
It is also possible that the reversion rate is much higher after
transient transfection because the process of calcium phosphate
transfection is itself mutagenic to the DNA template. To address
this possibility, a plasmid encoding both a wild-type chloram-
phenicol acetyl transferase and also a point mutant β-lactamase
(BLA E166Q) gene was transiently transfected into 293T cells
using the same protocol used to make viral vectors. The BLA
E166Qmutant is null over 8 orders of magnitude, and enzymatic
function can only be restored by the single nucleotide reversion
C496→G496 (Palzkill and Botstein, 1992). Plasmid was
recovered from Hirt supernatants of transfected cells and used
to transform electrocompetent E. coli. Reversion rate was
measured as the number of ampicillin + chloramphenicol-
resistant colonies divided by the number of chloramphenicol-
resistant colonies. Recovery of plasmid by the modified Hirt
method was approximately 1% of transfection input. As a
comparison, non-transfected plasmid DNA was directly trans-
formed into E. coli. Measured reversion rates comparing post-
transfected to non-transfected plasmid were not significantly
different, implying that the process of transfection itself did not
introduce mutations into the DNA plasmid template (Table 2).
RNAP may be responsible for reversions observed during
transient transfection
The above results suggest that either the RTs of HIV, MLV,
and ALV have finely tuned error rates that have converged due
to selective pressures and unknown evolutionary forces to be
approximately the same, or that perhaps, another polymerase
involved in the replicative cycle, namely RNAP, is responsible
for the reversions generated, at least in the transient transfection
system. With regards to the latter, rare errors made during
mRNA transcription would then simply be duplicated during
reverse transcription. Under the transient transfection condi-
tions employed, the ‘readout’ may be a measure of RNAP
fidelity and not that of RT. In order to test this hypothesis, we
constructed a self-inactivating (SIN) HIV-based vector in which
mutant bsd was driven by the cytomegalovirus (CMV)
immediate-early enhancer–promoter and placed within thedeleted region of the 3′ U3 (Fig. 3A). The second internal
cassette of the SRα promoter driving enhanced green
fluorescent protein (eGFP) provided an independent measure
of cellular transduction. Note that the bsd gene had an early stop
codon, making it null and also creating an AflII restriction
endonuclease site; removal or alteration of that codon in the
DNA template would eliminate the AflII site, facilitating the
screening process for mutations.
Vector was produced by transient transfection, and targets
were transduced at low MOI to reduce the number of double
integrants. Approximately 70 individual blasticidin-resistant
cell colonies were isolated, expanded, and genomic DNA
prepared. In order to examine both the 5′ and 3′ bsd genes of
each, unique PCR DNA primers were designed. Based upon the
PCR results, only 16 had single vector integrants, which were
further analyzed. For each of the 16, both 5′ and 3′ PCR
products were digested with AflII, and in each case, the AflII site
had been destroyed at both the 5′ and 3′ ends (Fig. 3B). This
was further confirmed by sequencing the bsd gene for each. For
all 16 revertants, the observed sequence change(s) at the 5′ end
was identical to that at the 3′ end (Table 3). The reversion rate
for this SIN vector was 4.1 × 10−5.
To demonstrate that two corrected bsd genes were not
required for positive cell selection in blasticidin, a SIN HIV
vector was constructed in which a CMV promoter-mutant bsd-
IRES-eYFP cassette was placed within the nef region. There
were no significant differences between the reversion rates of
this ‘single copy’ vector and that of the ‘double copy’ vector
(5.1 × 10−5 vs. 4.1 × 10−5). In addition, single copy revertants
survived and proliferated well even when the concentration of
blasticidin was increased 5-fold, from 10 to 50 μg/ml (data not
shown), suggesting that double copy revertants would not have
a survival advantage at the low concentrations of blasticidin that
were used.
Statistical analysis, coupled with the known HIV replica-
tive cycle, suggested two possible interpretations of the data:
either RNAP was much more (Nten-fold) error-prone than RT
or RT 1st strand was much more error prone than either
RNAP or RT 2nd strand. Since no second strand errors were
observed in this experiment, and in vitro data have not
established that RT 1st strand is much more error prone than
2nd strand (Bebenek et al., 1999; Boyer et al., 1992), these
data are consistent with RNAP being responsible for most of
the reversions generated when vector is made by transient
transfection.
Fig. 3. Double copy bsd mutant vectors. (A) Schematic of the SIN HIV-based plasmid vector in which the 1.4 kb reporter cassette (CMV-bsd) was placed within the
deleted region of the 3′ U3. The proviral form is shown below. Arrows indicate PCR primers for amplification of both the 5′ and 3′ CMV-bsd cassettes. (B) Southern
blot (using bsd coding sequence as 32P-labeled probe) of both the 5′ and 3′ LTR PCR products, cleaved with AflII as indicated above each lane. Arrow indicates
expected product for presence of AflII site; note clone 6 has two bands consistent with N1 integrant (and thus excluded from further analysis). ‘Pool’ indicates
blasticidin-resistant pooled transductants, each of which has one or more bsd genes. Arrows indicate positions of both uncut DNA (revertant) and Afl II-cut DNA
(mutant) and asterisks mark full-length PCR products.
Table 3
Sequence changes in bsd in SIN vector after transduction
DNA sequence a Frequency b (%) 5′ and 3′ Reversions? c
CAA GAA GAAd 6 (37) Yes
Δ6 TTA GAA GAA 2 (13) Yes
TGG GAA GAA 2 (13) Yes
AAA GAA GAA 1 (6) Yes
GAA GAA GAA 1 (6) Yes
TTA GAA GAA 1 (6) Yes
TGG GAA GAG 2 (13) Yes
TGG GGA GAA 1 (6) Yes
a Mutant sequence is T19AA GAA GAA, relative to bsd start codon. Changes
in the revertants are shown in bold; Δ6 refers to a deletion of 6 bp.
b Total of 16 revertants with single integrants.
c Determined by PCR and direct sequencing of bsd in both LTRs.
d Wild-type sequence.
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supernatant production
Although widely used for gene transfer purposes, produc-
tion of vector supernatant by transient transfection of 293T
cells is unquestionably artificial. Because of this, we decided
to determine whether reversion rate was similar when virus
was produced by an alternative method—recovery of a stably
integrated vector. Briefly, 293T cells were transduced at low
multiplicity of infection (MOI) with the replication-defective
vectors HIV-SN1-IY, HIV-FS1-IY, and HIV-WT-IY. Three
YFP + cell clones were picked and expanded for each
construct (Fig. 4A). PCR analysis of the cell clones using
HIV-specific DNA primers (normalized using β-actin-specific
DNA primers) suggested that each of these cell clones had 1
or 2 vector integrants. Vector was then recovered by
transiently transfecting the clones with VSV G expression
plasmid and titered on adherent human cells. Surprisingly, the
measured reversion rate was 4- to 18-fold lower than that of
vector produced by transient transfection. There were no
significant differences in reversion rates between indepen-
dently derived cell clones, and the results using one cell clone
of each construct are shown in Fig. 4B. The reversion rates
for the SN1 mutation on 293T and HOS TK-cells were3.6 × 10−6 and 4.3 × 10−6, respectively (for vector transcribed
from integrated proviral template). Vector produced from a
plasmid template by transient transfection had a significantly
higher reversion rate, 1.9 × 10−5 for 293T cells and
2.1 × 10−5 for HOS TK− cells. The reversion rates for the
FS1 mutation on 293T and HOS TK− cells were 2.9 × 10−6
and 2.7 × 10−6, respectively (for vector transcribed from
integrated proviral template). Vector produced from a plasmid
Fig. 4. Reversion rate of vector rescued from stable 293T producers. (A)
Schematic of method for generating stable producer cell lines. Vector made by
transient transfection was used to transduce 293T cells at low MOI. eYFP+ cell
clones (three for each vector) were selected and expanded. Vector was recovered
by transfecting stable cell clones with VSVG expression plasmid and harvesting
culture supernatant. (B) Measured reversion rates on 293T (closed diamond) and
HOS TK− (closed square) target cells for vector recovered from the stable cell
lines (provirus) or produced by transient transfection (plasmid). *P b 0.001
compared to the transiently produced vector.
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higher reversion rate, 3.4 × 10−5 for 293T cells and
5.1 × 10−5 for HOS TK− cells. As expected, reversion rate
was independent of target cell type. This was reproduced
several times, and in each case, the stable transductants gave
reversion rates that were 2.0–4.0 × 10−6. Weighted linear
regression revealed a significant main effect for method of
vector production (P b 0.001).
Discussion
Here, we describe a two-reporter genetic reversion assay to
quantify the fidelity of HIVand other retroviral vectors produced
by transient transfection. Reversion rate using this assay ranged
from 10−4 to 10−5, depending upon the reversion being
corrected. Fidelity was independent of retrovirus, pseudotyping
envelope, and target cell type. Neither propagation in bacteria
nor the actual process of transfection appeared to be responsible
for the generation of reversions. A novel SIN vector suggested
that reversions during transient transfection were generated by
RNAP and then simply duplicated by RT during cellular
transduction, and fidelity was significantly greater when vector
was rescued from a stable proviral integrant.Other investigators have suggested that the replicative
fidelity of HIV is much lower compared to that of other
retroviruses. Review of the published literature shows that in no
case were other retroviruses compared to HIV directly, using
precisely the same vector production method and reversion
assay, so it is difficult to conclude that HIV is in fact more error-
prone than other retroviruses. Here, we used the identical
reporter cassette for all three retroviruses tested, which were all
produced by the same method of transient transfection of the
same cell type. Use of a bicistronic cassette with an auto-
fluorescent reporter along with a wild-type bsd provided both an
internal and external normalization control, respectively,
allowing for precise quantitation of reversion errors. Thus, the
result here that the reversion rates of HIV, MLV, and ALV were
the same is not in contradiction with the published literature.
Most of the viral mutations that arise during retroviral
replication have long been attributed to RT, which is not thought
to have proof-reading capability but simply an intrinsic fidelity.
In addition, no known cellular factors participate directly in
reverse transcription. Recently, it has become clear that the
cytidine deaminases APOBEC3G and 3F (and perhaps others)
may mold HIV sequences, if not those of endogenous and other
exogenous retroviruses (Esnault et al., 2005; Turelli and Trono,
2005), resulting in G to A changes and leading to A-T richness
of the genome (Conticello et al., 2003; Goff, 2003; Zhang et al.,
2003). Although the vectors here did not include vif to
counteract the editing enzymes, 293T cells do not express
APOBEC3G or 3F. In addition, G to A changes would not have
corrected either the stop codon or frameshift mutations in the
mutant bsd genes used here. We conclude that particular
hypermutation system was non-operational here, and the
mutations observed were most likely due to a polymerase,
namely either RT or RNAP.
Cell-free RT has a calculated error rate that is orders-of-
magnitude higher than that observed in cell-based assays
(Mansky and Temin, 1995), suggesting that there are other viral
or cellular factors that increase replicative fidelity in the cell.
Most of the cell-based assays cannot distinguish between errors
made by RT and RNAP and only recently have efforts been
directed towards determining the relative contributions of RT
and RNAP to replicative errors. For example, Dougherty and
colleagues sequenced a total of 215 paired LTRs after HIV
vector transduction of cells and concluded that RT was in fact
responsible for most of the observed mutations (O'Neil et al.,
2002). However, intervector recombination (and not RT error)
could not be wholly excluded as a cause of single LTR
mutations. Of note is the use of a stable cell line to produce the
viral vectors used for their experiments.
Here, we designed a SIN vector in which the bsd mutant
reporter was located in the 3′ LTR and thus duplicated to the 5′
LTR after cellular transduction. In all cases in which a single
vector integrant was found in the blasticidin-resistant targets,
the same mutation in bsd was present in both LTRs. This
suggests that either all the mutations observed were created in
the vector-producing cell by a cellular enzyme and then simply
duplicated by RT in the target cell or that the mutations all arose
during first strand RT (and were then duplicated during second
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analysis suggests that if this was the case, then first strand
cDNA synthesis must have at least a 5- to 10-fold higher error
rate than that of second strand. In vitro, cell-free data suggest
that second strand cDNA synthesis has a similar if not lower
fidelity compared to first strand (Boyer et al., 1992; Kerr and
Anderson, 1997). It should be emphasized, however, that our
results were obtained in a transient transfection system, and
vector recovered from stable integrants had significantly greater
fidelity. Experiments are now in progress to determine whether
similar results (i.e., duplication of LTR mutations) are obtained
in a stable integrant system in which the overall reversion rate is
closer to 10−6.
It is not clear why the reversion rate of vector in the
transient transfection system was much higher than that of the
stable integrants. Although previous results have suggested
that the process of transient transfection may be mutagenic
(Lebkowski et al., 1984), we did not observe this after calcium
phosphate transfection of 293T cells. Reversion rate of
plasmid recovered from Hirt supernatants was essentially
identical to that of purified, untransfected plasmid, indepen-
dent of the amount of DNA transfected. Although it could be
argued that mutagenized plasmids are recovered with less
efficiency than unmutagenized ones, this was not true for
previous work (Calos et al., 1983; Lebkowski et al., 1984).
Prior to Hirt supernatant preparation, transfected cells were
extensively washed to remove any extracellular DNA, and the
plasmid yields of 1% or less were approximately as expected
for cell-associated DNA. Whether the recovered DNA was in
fact nuclear is unknown.
It is possible that the mutagenicity of transient transfection
observed in the past depended upon the method of transfection,
the recipient cell type, and the plasmid itself. It is notable that
some of the prior work demonstrating increased mutagenicity of
transient transfection involved plasmids which contained the
SV40 origin of replication, which was absent from all of the
plasmids used here. Many of the mutations after transient
transfection observed previously were likely due to acid
depurination or cytidine deamination, the former perhaps
secondary to transit through endosomes and the latter due to
inherent instability of the purine base or the action of cellular
deaminases. In addition, previous investigators did not use
293T cells (which lack cytidine deaminases) or chloroquine
during the transfection process. Based upon these reasons and
the data presented in Tables 1 and 2, we do not believe that the
transfection process here was in itself mutagenic, although it
cannot be completely excluded.
While MLV-based gene therapy vectors are routinely
produced from stable producer cell lines, HIV vector super-
natants are typically produced by transient transfection of 293T
cells, as was performed here, since transient transfection usually
results in higher vector titers compared to stable lentiviral
producers. Unfortunately, the trade-off for higher titers may be
reduced fidelity. Efforts to maximize both titer and fidelity are
clearly desirable, and novel vector production methods (i.e., use
of helper-dependent adenoviral-HIV chimeric vectors) may
have utility in this regard.Precisely how the method of vector production influences
fidelity is uncertain, but we speculate that the amount or state of
the DNA template may be critical. For example, the stable 293T
producers used here had only one or two integrated proviruses
in each cell, whereas after transient transfection hundreds if not
thousands of plasmids are likely introduced into each
transfected 293T cell. As an example, for Chinese hamster
ovary cells, which are transfected at approximately half the
efficiency of 293Tcells, there was a maximum of approximately
100,000 plasmid molecules per cell 4 h after transfection
(Batard et al., 2001). Overall, b5% of transfected cells had
fewer than 3000 plasmids per cell. In another study using
radiolabeled plasmids, after calcium phosphate transfection,
less than 10% of input DNAwas found in the nuclear fraction,
remaining intact (Orrantia and Chang, 1990).
Based upon this, we speculate that when vector was made by
transient transfection, on average approximately 2000–5000
plasmids entered each 293T cell, and of those 10% made it to
the nucleus intact. It is therefore possible that cellular
transcription factors or subunits of RNAP critical to fidelity
may be limiting. Efforts to titrate such factors by co-transfecting
plasmids containing solely an intact LTR and demonstrating
subsequent reduced fidelity have thus far been unsuccessful. In
addition, decreasing or increasing the amount of plasmid DNA
used during the transient transfection over a 10-fold dynamic
range did not statistically alter resultant reversion rate (not
shown).
Alternatively, the exact state of the template may be critical.
Transiently transfected plasmid is initially unchromatinized and
much remains so, especially when introduced in large amounts,
whereas integrated proviruses exist in a nucleosomal structure.
Actively transcribed proviruses likely have additional cellular
factors bound which maintain the open chromatin structure and
participate in transcriptional regulation. Whether those factors
have a direct role in transcriptional fidelity is uncertain, but one
or more may serve to recruit RNAP subunits that are critical to
the intrinsic fidelity or chain cleavage activity of the core
polymerase. These may thus be present in the vicinity of stable
integrants but absent from transiently transfected DNA
templates. We thus speculate that after transient transfection if
unchromatinized plasmid is utilized as transcription template
fidelity may be lower.
Although the relative fidelity of RNAP has been measured in
cell-free systems with or without specific transcription factors
(Koyama et al., 2003; Thomas et al., 1998; Wang and Hawley,
1993), it has never been accurately quantified in cell-based
assays. The error rate of mammalian genomic DNA replication
is thought to be on the order of 10−9 to 10−10; there are multiple
reasons to believe that RNAP fidelity may be orders-of-
magnitude lower. For example, depending upon the particular
mRNA, in each cell at steady state, there are tens to thousands of
copies of that species. Although some mRNAs are long lived,
most degrade relatively rapidly, on the order of minutes to
hours. Mechanisms such as nonsense-mediated decay exist to
rapidly degrade errant mRNAs that have early stop codons
(Hentze and Kulozik, 1999; Mashima et al., 1992; Zhang and
Maquat, 1996). Furthermore, ribosomal translational error rate,
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and Gallant, 1982; Weickert and Apostol, 1998). Taken
together, these arguments suggest that there might be minimal
selective pressure for RNAP to be of extremely high fidelity. It
is conceivable that RT, which has its own intrinsic fidelity, may
simply rely on RNAP to generate replicative errors.
Unexpectedly, in the SIN vector experiment, we did not
observe any templates consistent with genomic recombination,
suggesting that the recombination rate in the transient
transfection system is b7%. Recombination is a driving force
in HIVevolution and is estimated to occur more frequently than
point mutations (An and Telesnitsky, 2002; Shriner et al., 2004;
Zhuang et al., 2002). HIV infection of T lymphocytes and
macrophages generated nine or more recombination events per
round of replication, and comparisons with SNV and MLV
suggest HIV may be up to ten times more recombinogenic than
simple retroviruses (Levy et al., 2004; Onafuwa et al., 2003;
Rhodes et al., 2005). Of note, vector recombination here would
not per se result in blasticidin resistance. In our experiments,
cell revertants which had multiple integrants or proviruses with
gross rearrangements were excluded, due to the difficulty of
interpreting results, and omission of those transduced cells from
further analyses may have underestimated the recombination
rate, especially since dual infection is thought to be required for
recombination (Fernandez-Medina et al., 1999). Recombination
events in cells with single integrants without gross rearrange-
ments would have been scored, however.
In conclusion, we have demonstrated that three different
retroviruses, including HIV, have the same replicative fidelity.
Results from transient transfection suggest that the errors likely
occurred in the producer cell, and those changes were then
simply duplicated by RT. The fact that stable producer cell lines
generate vector with significantly greater fidelity may have
important implications for lentiviral gene transfer.
Materials and methods
Retroviral vectors and expression plasmids
The HIV-1, MLV, and avian leukosis virus (ALV) vectors
used in these studies are shown in Fig. 1A. The parent construct
for all HIV vectors was pHIV-IRES-eYFP, which has deletions
in vif, vpr, vpu, env, and nef and was derived from the NL4-3
isolate (Adachi et al., 1986). Wild-type bsd was inserted just
upstream of the IRES element to create HIV-WT-IY. Null
mutants of the bsd gene were created by PCR-based
mutagenesis (SN1, 5′-TGTGCATAACTC-3′, where the under-
lined nucleotide is mutated; SN2, 5′-GAATTCGCCCT-
TGGTCTAGACTAAACCATGGCCAAGCCTTAG-3′; FS2,
5′-GGTCTAGAAACCATGGCCAAGGCCTTTGTCTC-3′;
antisense for all mutants 5′-GGTTAGCCCTCCCACACA-
TAACTGCA-3′) or restriction digest with EagI followed by
fill-in reaction with Klenow fragment of DNA polymerase
(FS1). All versions of bsd were sequenced by the dideoxy
method to confirm the introduced mutation. The ALV-based
vector, based on the pRCAS series, is replication-competent in
avian cells since it contains gag, pol, and env genes and thecassette replaces src, but it is replication-defective in mamma-
lian cells that lack the ALV receptor tva. The replication-
defective MLV vector was based upon the pBABE series, but it
has an extended packaging sequence to increase titer.
The self-inactivating (SIN) vector pHIV-SRα-IRES-eGFP-
CMV-AflII was constructed in three steps. The bsd gene with an
early stop codon/AflII site was amplified by PCR using wild-
type bsd as template and oligonucleotide primers 5′-GCCGCT-
CGAGAAACCATGGCCAAGCCTTTGTCTTAAGAA-
GAATCC-3′ and 5′-GGAATTCTTAGCCCTCCCACA-3′ and
cloned into pCR2.1 (Invitrogen Life Technologies). This was
digested with XhoI and EcoRI to release a ∼450 bp fragment,
which was subcloned into pCI (Promega), which had been
modified with an oligonucleotide linker to add an MluI site at
position 4007. MluI digest released the 1.4 kb CMV promoter
and mutant bsd gene, which was then subcloned into MluI-
cleaved pHIV-SRα-IRES-eGFP-X-M, which has a 1.9 kb SRα-
IRES-eGFP expression cassette in nef and a convenientMluI site
just 5′ of the 400 bp deletion in the 3′ U3.
Cell lines
All cells were maintained in water-jacketed, 5% CO2
incubators at 37 °C, except as indicated. Adherent human cell
lines used in this study were cultured in Dulbecco's modified
Eagle's medium with high glucose, 10% fetal bovine serum
(Gemini Bio-Products, Woodland, CA), penicillin, and strepto-
mycin (complete DMEM). Where indicated, complete DMEM
was supplemented with 10 μg/ml blasticidin S (Invitrogen Life
Technologies). Stable cell lines with single integrated pro-
viruses were constructed by transducing 293T cells at low MOI
with VSV G-pseudotyped HIV vector encoding a mutant bsd
gene. Three independent clonal cells lines for each HIV vector
were isolated by repeated rounds of single colony selection, and
vector integrant copy number was determined by Southern
blotting of genomic DNA cleaved with EcoRI and hybridized
using an HIV-specific probe and also by semi-quantitative PCR,
using β-actin as a normalization control.
Preparation and titration of vector supernatant
Two methods were used to generate replication-defective
pseudotyped particles. Vector supernatants were prepared either
by transient transfection of 293T cells by calcium phosphate co-
precipitation with equimass amounts of pME-VSV G (encoding
VSV G) and the HIVor ALV vector (van Maanen et al., 2003),
or clonal cell lines bearing one or two HIV vector integrants
were transiently transfected with the envelope plasmid alone.
MLV vector supernatant was produced by co-transfection of the
293T cells with the MLV vector, pHIT60 (CMV IE promoter
driving MLV gag-pol) (Soneoka et al., 1995), and VSV G
envelope. Supernatants were harvested 72 h later and inoculated
directly onto adherent target cells. eYFP vector titers were
determined on 293T cells by end-point dilution and enumerat-
ing eYFP+ cells 3 days later by epifluorescence microscopy.
The titers for VSV G-pseudotyped HIV were typically 2 × 107
IU/ml for virus produced by transient transfection and 5–
415M.M. Laakso, R.E. Sutton / Virology 348 (2006) 406–41710 × 106 IU/ml for virus produced from stable cell lines. In
select experiments, HIV vector was co-transfected with ADA
envelope expression plasmid and titered on HOS cells
expressing CD4 and CCR5 (GHOST HI 5 cells, obtained
from the AIDS Reference and Reagent Repository (Morner et
al., 1999)). For both ALVandMLV, target cells were typically at
low (10–20%) confluence and actively proliferating. For HIV,
target cells were at 50% confluence.
Reversion assay for determination of retrovirus reversion rate
Viral supernatant was used to transduce human 293T, HOS
TK− or HeLa cell lines at an MOI of 1–3. In this range of MOI,
reversion rate was linear in that increased MOI resulted in a
corresponding increase in cells with reversion phenotype. After
3 days, cells were selected by passage into complete DMEM
supplemented with 10 μg/ml blasticidin. Cells were refed after
3–5 days, and colonies were stained using 1% crystal violet in
30% methanol and 10% acetic acid after 9 days. Reversion rate
measurements were based on the number of blasticidin-resistant
colonies, and reversion rate was calculated as shown in Fig. 1C.
eYFP titer was determined separately by end-point titration for
each revertant vector. All reversion rate experiments were
performed a minimum of two times, with three measurements
per vector per target cell line for each experiment. Thus, each
reversion rate measurement is based on at least 2 × 107 target
cells for each cell line tested, typically resulting in tens or
hundreds of clonal revertants, respectively, for the stable or
transient producers.
Blasticidin-resistant cell revertants after transduction with
the HIV SIN vector were clonally isolated by limiting dilution
and expanded. Genomic DNA was extracted using DNAzol
(Boehringer Mannheim) and used for PCR amplification of bsd
in both the 5′ LTR (5′-GTGTACGGTGGGAGGTCTATAT-3′
and 5′-TTAATACCGACGCTCTCGCACCCAT-3′) and 3′
LTR (5′-GTGCCACGTTGTGAGTTGGATAGTTGTG-3′ and
5′-TCCCACACATAACCAGAGGGCAGCAATT-3′). For am-
plification of the 5′ LTR, genomic DNA (300 ng) was used in a
50 μl reaction with Expand Long Template PCR system (Roche
Diagnostics), conditions as follows: 94 °C for 2 min, followed
by 40 cycles of 94 °C for 30 s, 51 °C for 30 s, and 68 °C for 90 s,
then a final elongation step at 72 °C for 7 min. For amplification
of the 3′ LTR, annealing temperature was 59 °C. PCR products
were directly sequenced by the automated dideoxy method.
Determination of reversion rate after transfection
Plasmids were liquid amplified in E. coli and purified by
alkaline lysis followed by two rounds of CsCl equilibrium
ultracentrifugation. Plasmid pTP123-TEM-E166Q (Palzkill and
Botstein, 1992) encoding the point mutant β-lactamase gene
BLA E166Q was used to measure reversions due to calcium
phosphate transient transfection. Plasmid (≤1% of input DNA)
was recovered from transfected cells after 39 h using a modified
Hirt lysate procedure after washing cells extensively with
phosphate-buffered saline (Arad, 1998). Ten nanograms of this
plasmid or non-transfected plasmid (representing approximate-ly 108 copies of pTP123-TEM-E166Q) was transformed into
electrocompetent TOP10F E. coli, and bacteria were selected on
LB plates supplemented with chloramphenicol plus ampicillin
or chloramphenicol alone.
With regards to reversions made during stable transfection,
purified plasmids were directly transfected into 293T cells using
the cationic lipid reagent DOTAP (Goldman et al., 1997). After
1.5 h, cells were refed with complete DMEM, and after an
additional 30 h, cells were selected in complete DMEM
supplemented with 10 μg/ml blasticidin. Cells were refed
every 3–5 days, and colonies were stained and enumerated after
9 days.
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